Skip to content Skip to navigation

Provigil, Nuvigil, Modafinil Antitrust Settlements

Share
Active: 
Open
Settlement Structure: 
Case Summary: 

An antitrust class action and an antitrust case brought by the California Attorney General (CAAG) on the same topic are being settled at the same time. The suits claim that drug companies conspired to keep prices of the original drug Provigil high by delaying the introduction of generics and (in the CAAG suit) of Nuvigil.

The class action named as defendants Cephalon, Inc., Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc. and Mylan, Inc., Sun Pharmaceuticals Industries, Ltd. (successor-in-interest to Ranbaxy Laboratories, Ltd.) and Ranbaxy Pharmaceuticals, Inc.

The CAAG case named as defendants Teva Pharmaceutical Industries Ltd. and its wholly-owned subsidiaries Cephalon, Inc., Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.

Docket Number: 
06-CV-1833 and 19-CV-03281
Company: 
Teva Pharmaceuticals
Class Period: 
Saturday, June 24, 2006 to Thursday, August 8, 2019
Filing Deadline: 
Wednesday, January 15, 2020
Objection Deadline: 
Wednesday, January 15, 2020
Exclusion Deadline: 
Friday, December 6, 2019
Final Approval Hearing: 
Wednesday, February 26, 2020
Front Label of Provigil Container